Safety of procuring research tissue during a clinically indicated kidney biopsy from patients with lupus: data from the Accelerating Medicines Partnership RA/SLE Network.
Safety of procuring research tissue during a clinically indicated kidney biopsy from patients with lupus: data from the Accelerating Medicines Partnership RA/SLE Network.
复制标题
DOI：
10.1136/lupus-2021-000522
复制
发表时间：
2021-08
影响因子：
3.9
通讯作者：
Buyon JP
中科院分区：
文献类型：
--
作者：
Deonaraine KK;Carlucci PM;Fava A;Li J;Wofsy D;James JA;Putterman C;Diamond B;Davidson A;Fine DM;Monroy-Trujillo J;Atta MG;Haag K;Rao DA;Apruzzese W;Belmont HM;Izmirly PM;Wu M;Connery S;Payan-Schober F;Furie RA;Berthier CC;Dall'Era M;Cho K;Kamen DL;Kalunian K;Anolik J;Ishimori M;Weisman MH;Accelerating Medicines Partnership RA/SLE network;Petri MA;Buyon JP
In lupus nephritis the pathological diagnosis from tissue retrieved during kidney biopsy drives treatment and management. Despite recent approval of new drugs, complete remission rates remain well under aspirational levels, necessitating identification of new therapeutic targets by greater dissection of the pathways to tissue inflammation and injury. This study assessed the safety of kidney biopsies in patients with SLE enrolled in the Accelerating Medicines Partnership, a consortium formed to molecularly deconstruct nephritis. 475 patients with SLE across 15 clinical sites in the USA consented to obtain tissue for research purposes during a clinically indicated kidney biopsy. Adverse events (AEs) were documented for 30 days following the procedure and were determined to be related or unrelated by all site investigators. Serious AEs were defined according to the National Institutes of Health reporting guidelines. 34 patients (7.2%) experienced a procedure-related AE: 30 with haematoma, 2 with jets, 1 with pain and 1 with an arteriovenous fistula. Eighteen (3.8%) experienced a serious AE requiring hospitalisation; four patients (0.8%) required a blood transfusion related to the kidney biopsy. At one site where the number of cores retrieved during the biopsy was recorded, the mean was 3.4 for those who experienced a related AE (n=9) and 3.07 for those who did not experience any AE (n=140). All related AEs resolved. Procurement of research tissue should be considered feasible, accompanied by a complication risk likely no greater than that incurred for standard clinical purposes. In the quest for targeted treatments personalised based on molecular findings, enhanced diagnostics beyond histology will likely be required.
登录
查看更多内容
影响因子：
--
作者：
Petri, Michelle;Orbai, Ana-Maria;Alarcon, Graciela S.;Gordon, Caroline;Merrill, Joan T.;Fortin, Paul R.;Bruce, Ian N.;Isenberg, David;Wallace, Daniel J.;Nived, Ola;Sturfelt, Gunnar;Ramsey-Goldman, Rosalind;Bae, Sang-Cheol;Hanly, John G.;Sanchez-Guerrero, Jorge;Clarke, Ann;Aranow, Cynthia;Manzi, Susan;Urowitz, Murray;Gladman, Dafna;Kalunian, Kenneth;Costner, Melissa;Werth, Victoria P.;Zoma, Asad;Bernatsky, Sasha;Ruiz-Irastorza, Guillermo;Khamashta, Munther A.;Jacobsen, Soren;Buyon, Jill P.;Maddison, Peter;Dooley, Mary Anne;van vollenhoven, Ronald F.;Ginzler, Ellen;Stoll, Thomas;Peschken, Christine;Jorizzo, Joseph L.;Callen, Jeffrey P.;Lim, S. Sam;Fessler, Barri J.;Inanc, Murat;Kamen, Diane L.;Rahman, Anisur;Steinsson, Kristjan;Franks, Andrew G., Jr.;Sigler, Lisa;Hameed, Suhail;Fang, Hong;Ngoc Pham;Brey, Robin;Weisman, Michael H.;McGwin, Gerald, Jr.;Magder, Laurence S.
通讯作者：
Magder, Laurence S.
影响因子：
13.2
作者：
Parikh, Samir, V;Almaani, Salem;Rovin, Brad H.
通讯作者：
Rovin, Brad H.
影响因子：
30.5
作者：
Arazi, Arnon;Rao, Deepak A.;Goldman, Daniel H.
通讯作者：
Goldman, Daniel H.
DOI：
10.1016/j.jvir.2019.04.017
发表时间：
2019-08-01
影响因子：
2.9
作者：
Patel, Indravadan J.;Rahim, Shiraz;Weinberg, Ido
通讯作者：
Weinberg, Ido
DOI：
10.1002/art.41632
发表时间：
2021-06
期刊：
Arthritis & rheumatology (Hoboken, N.J.)
影响因子：
--
作者：
Izmirly PM;Parton H;Wang L;McCune WJ;Lim SS;Drenkard C;Ferucci ED;Dall'Era M;Gordon C;Helmick CG;Somers EC
通讯作者：
Somers EC